Primary prevention implantable cardioverter-defibrillators and survival in older women

JACC: Heart Failure

Volumn 3, Issue 2, 2015, Pages 159-167

  Zeitler, Emily P ^a,b   Hellkamp, Anne S ^b   Fonarow, Gregg C ^c   Hammill, Stephen C ^d   Curtis, Lesley H ^b   Hernandez, Adrian F ^a,b   Al Khalidi, Hussein R ^b   Curtis, Jeptha P ^e   Heidenreich, Paul A ^f   Anstrom, Kevin J ^b   Peterson, Eric D ^a,b   Mark, Daniel B ^a,b   Hammill, Bradley G ^a   Sanders, Gillian D ^b   Al Khatib, Sana M ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Heart failure; Implantable cardioverter defibrillator; Mortality; Primary prevention; Women

Indexed keywords

AGE; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY PREVENTION; SEX; SURVIVAL; EPIDEMIOLOGY; HEART LEFT VENTRICLE FUNCTION; PROPENSITY SCORE; REGISTER; UNITED STATES; VERY ELDERLY;

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; MALE; PRIMARY PREVENTION; PROPENSITY SCORE; REGISTRIES; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84959935665     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.09.006     Document Type: Article

References (32)

1. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEngl J Med 2005, 352:225-237. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators, [published correction appears in N Engl J Med 2005;352:2146].
2. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G. Arandomized study of the prevention of sudden death in patients with coronary artery disease. NEngl J Med 1999, 341:1882-1890. for the Multicenter Unsustained Tachycardia Trial Investigators, [published correction appears in N Engl J Med 2000;342:1300].
3. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. NEngl J Med 2004, 350:2151-2158. for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators.
4. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med 2002, 346:877-883. for the Multicenter Automatic Defibrillator Implantation Trail II Investigators.
5. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. JAm Coll Cardiol 2008, 51:e1-e62. [published corrections appear in J Am Coll Cardiol 2009;53:1473 and J Am Coll Cardiol 2009;53:147].
6. Redberg R.F. Disparities in use of implantable cardioverter-defibrillators: moving beyond process measures to outcomes data. JAMA 2007, 298:1564-1566.
7. Curtis L.H., Al-Khatib S.M., Shea A.M., Hammill B.G., Hernandez A.F., Schulman K.A. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007, 298:1517-1524.
8. Hernandez A.F., Fonarow G.C., Liang L., et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007, 298:1525-1532.
9. Albert C.M., Quigg R., Saba S., et al. Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy. Am Heart J 2008, 156:367-372. for the DEFINITE Investigators.
10. Ghanbari H., Dalloul G., Hasan R., et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169:1500-1506.
11. Henyan N.N., White C.M., Gillespie E.L., Smith K., Coleman C.I., Kluger J. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. JIntern Med 2006, 260:467-473.
12. Russo A.M., Poole J.E., Mark D.B., et al. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. JCardiovasc Electrophysiol 2008, 19:720-724.
13. Santangeli P., Pelargonio G., Dello Russo A., et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm 2010, 7:876-882.
14. Zareba W., Moss A.J., Jackson Hall W., et al. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. JCardiovasc Electrophysiol 2005, 16:1265-1270. MADIT II Investigators.
15. MacFadden D.R., Crystal E., Krahn A.D., et al. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database. Ann Intern Med 2012, 156:195-203.
16. Bhavnani S.P., Pavuluri V., Coleman C.I., et al. Thegender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study. Pacing Clin Electrophysiol 2013, 36:878-884.
17. Chen H.A., Hsia H.H., Vagelos R., Fowler M., Wang P., Al-Ahmad A. The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators. Pacing Clin Electrophysiol 2007, 30:390-394.
18. Hernandez A.F., Fonarow G.C., Hammill B.G., et al. Clinical effectiveness of implantable cardioverter-defibrillators among Medicare beneficiaries with heart failure. Circ Heart Fail 2010, 3:7-13.
19. Hammill S.C., Stevenson L.W., Kadish A.H., et al. Review of the registry's first year, data collected, and future plans. Heart Rhythm 2007, 4:1260-1263.
20. National Cardiovascular Data Registry. Available at: Accessed November 8, 2014. https://www.ncdr.com/webncdr/home/.
21. Al-Khatib S.M., Hellkamp A., Curtis J., et al. Non-evidence-based ICD implantations in the United States. JAMA 2011, 305:43-49.
22. Messenger J.C., Ho K.K., Young C.H., et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. JAm Coll Cardiol 2012, 60:1484-1488. NCDR Science and Quality Oversight Committee Data Quality Workgroup.
23. Fonarow G.C., Abraham W.T., Albert N.M., et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004, 148:43-51.
24. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006, 296:2217-2226. OPTIMIZE-HR Investigators and Coordinators.
25. Curtis L.H., Greiner M.A., Hammill B.G., et al. Representativeness of a national heart failurequality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. Circ Cardiovasc Qual Outcomes 2009, 2:377-384.
26. Hammill B.G., Hernandez A.F., Peterson E.D., Fonarow G.C., Schulman K.A., Curtis L.H. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 2009, 157:995-1000.
27. Rosenbaum P.R., Rubin D.B. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985, 39:33-38.
28. Chen J., Normand S.L., Wang Y., Krumholz H.M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA 2011, 306:1669-1678.
29. Kremers M.S., Hammill S.C., Berul C.I., et al. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm 2013, 10:e59-e65.
30. Al-Khatib S.M., Hellkamp A., Bardy G.H., et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA 2013, 309:55-62.
31. Stewart G.C., Chen C.-Y., Stevenson L.W., et al. Outcomes among Medicare beneficiaries are optimized when primary ICD implant occurs during an elective rather than unplanned hospitalization (abstr). Circulation 2013, 128:A11117.
32. Al-Khatib S.M., Hellkamp A.S., Hernandez A.F., et al. Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?. Circulation 2012, 125:1094-1101.